Published in final edited form as:

Adv Immunol. 2014 ; 122: 91–128. doi:10.1016/B978-0-12-800267-4.00003-1.

Recognition of tumors by the innate immune system and natural killer cells

Assaf Marcus, Benjamin G. Gowen, Thornton W. Thompson, Alexandre Iannello, Michele Ardolino, Weiwen Deng, Lin Wang, Nataliya Shifrin, and David H. Raulet¹

Department of Molecular and Cell Biology and Cancer Research Laboratory, University of California, Berkeley 94720-3200

Abstract

In recent years, roles of the immune system in immune surveillance of cancer have been explored using a variety of approaches. The roles of the adaptive immune system have been a major emphasis, but increasing evidence supports a role for innate immune effector cells such as natural killer (NK) cells in tumor surveillance. Here, we discuss some of the evidence for roles in tumor surveillance of innate immune cells, particularly NK cells and other immune cells that express germline-encoded receptors that are often labeled NK receptors. The impact of these receptors and the cells that express them on tumor suppression are summarized. We discuss in detail some of the pathways and events in tumor cells that induce or upregulate cell surface expression of the ligands for these receptors, and the logic of how those pathways serve to identify malignant, or potentially malignant cells. How tumors often evade tumor suppression mediated by innate killer cells is another major subject of the review. We end with a discussion of some of the implications of the various findings with respect to possibly therapeutic approaches.

1. INTRODUCTION

Research performed over the last two decades has provided much evidence supporting a role for the immune system in controlling cancer. Seminal studies showed that important components of the immune system such as perforin (van den Broek et al., 1996), interferon- γ (Dighe et al., 1994) and lymphocytes (Shankaran et al., 2001) can limit the outgrowth of transplanted, carcinogen-induced, and spontaneous tumors. These initial studies were followed by an explosion of clinical and experimental evidence describing how immune cells and molecules can influence the development of cancer (Vesely et al., 2011). Although certain immune responses can protect the host from neoplasia, other immune processes such as chronic inflammation can promote the initiation or progression of cancer (Schreiber, Old and Smyth, 2011). Notably, these contradictory roles of the immune system can manifest themselves in the same tumor model, illustrating the complex interaction between the immune system and the tumor (Swann et al., 2008).

Before discussing the role of the innate immune system in tumor surveillance, it is useful to briefly summarize the known role of the adaptive immune system. Many studies have

¹Corresponding author: raulet@berkeley.edu.

sought to clarify the cellular and molecular components responsible for the immune system's anti-tumor activities. There is much evidence that certain adaptive immune cells, specifically CD8⁺ T cells and Th1-polarized CD4⁺ T cells, can exert anti-tumor effects by recognizing tumor-specific antigens presented on MHC molecules (Diamond et al., 2011; van der Bruggen et al., 1991). These T cell antigens are derived from oncogenic viral products, mutations in cellular genes, and/or host proteins that are normally absent in adult animals but aberrantly expressed by cancer cells.

Acting as cell-extrinsic tumor suppressor mechanisms, these adaptive immune responses are thought to limit the establishment of certain types of cancer, which may therefore never be detected clinically. Indeed, immunocompromised humans and mice have significantly higher rates of numerous cancers of both viral and non-viral etiology (Vesely et al., 2011). However, in some cases tumor cells can escape the selective pressure from the immune system by acquiring mutations or other changes that allow tumor progression in the face of an ongoing immune response (Dunn et al., 2002; Schreiber, Old and Smyth, 2011). The functional consequence of this selective pressure by the immune system, also known as 'immunoediting', is demonstrated by the observation that tumors transplanted from an immune-deficient animal to a syngeneic immune-competent animal are often rejected by the recipient's immune system, whereas tumors that arise in immune-competent animals generally grow unimpeded after transplantation (O'Sullivan et al., 2012; Shankaran et al., 2001). Observations made in advanced tumors from patients lend further support to the existence of immunosurveillance mechanisms. For example, many tumor cells contain mutations affecting the MHC I processing pathway, presumably to avoid recognition by CD8⁺ T cells (Chen et al., 1996; Garrido et al., 1995; Seliger et al., 2001), while other tumors undergo selection for loss of peptide sequences that can serve as antigens for T cells (Matsushita et al., 2012). Taken together, these studies suggest that T cells exert strong selective pressure on tumors both in mice and in humans.

Although the importance of T cells in immunosurveillance is supported by considerable data, the adaptive immune system is not the sole mediator of anti-tumor immunity. Indeed, many innate leukocytes can differentiate normal cells from tumor cells and mediate important tumor suppressive functions. Whereas conventional T cells recognize cancer cells using a rearranged antigen receptor with myriad specificity for tumor antigens, innate cells express a fixed set of germline-encoded receptors, suggesting that the molecular basis of cancer surveillance by innate cells is fundamentally different from that of the adaptive immune system. Nevertheless, adaptive immune cells express germline receptors (such as NKG2D on CD8⁺ T cells), and these receptors can play an important role in driving adaptive immune responses (Andre et al., 2011). Furthermore, the adaptive response is amplified by, and in some cases may be dependent on, innate recognition mechanisms. One example to consider in the purview of this review is the documented capacity of NK cells, an innate component of the immune system, to induce dendritic cell maturation, which may amplify T cell responses (Moretta et al., 2005). Various other innate lymphoid cell types (ILCs), which are only now being characterized functionally, may also turn out to play roles in initiating adaptive responses to tumors. This review will focus on the role of innate immunity in detecting and preventing cancer, with particular emphasis on the receptors and ligands mediating innate recognition of tumor cells.

2. INNATE CELLS AND EFFECTOR MOLECULES IN TUMOR SURVEILLANCE

The role of the adaptive immune system in tumor surveillance has been well studied, but the innate immune system also plays a role. Natural killer cells are perhaps the best-studied mediators of innate immunosurveillance of cancer. The original characterization of NK cells noted their potent ability to kill tumor cells in vitro without prior sensitization, and numerous early studies suggested the potential for NK cells to mediate anti-tumor responses. Many transplanted tumor cells are rejected in an NK cell-dependent manner (Diefenbach et al., 2001; Ljunggren and Karre, 1985; Seaman et al., 1987), and early experiments suggested that perforin production by NK cells protected mice from methylcolanthrene (MCA)-induced sarcomas (van den Broek et al., 1996). Later, more direct, evidence showed that NK cells (in some cases in cooperation with NKT cells) eliminate many MCA-induced sarcomas (O'Sullivan et al., 2012; Smyth, Crowe and Godfrey, 2001). Clinical evidence suggests that NK cell infiltrates in tumor biopsies are associated with favorable prognoses in cancer patients (Coca et al., 1997; Ishigami et al., 2000), and therapies aimed at boosting the tumoricidal activity of NK cells are the subject of much clinical interest (Ames and Murphy, 2013). Additional studies have shown a role for other innate lymphocyte populations in tumor surveillance. Gamma/delta T-cells are another class of cytolytic innate lymphoid cells that can lyse tumor cells. $\gamma\delta$ T-cells have been shown to limit cancer incidence in models of carcinogen-induced skin cancer (Girardi et al., 2001) and a transgenic model of prostate adenocarcinoma (Liu et al., 2008). In addition, NKT cells can cooperate with NK cells to limit tumorigenesis in MCA-treated mice (Crowe, Smyth and Godfrey, 2002; Smyth, Crowe and Godfrey, 2001).

Innate cells can control cancer by directly interacting with tumor cells, and/or augmenting the activities of other cells in the tumor microenvironment. Direct tumor cell lysis by NK cells is thought to be mediated principally by perforin, as shown in vivo and in vitro (Davis, Smyth and Trapani, 2001; Hayakawa et al., 2002; Kagi et al., 1994; Lee et al., 1996; Smyth et al., 1999; van den Broek et al., 1996; van den Broek et al., 1995; Vermijlen et al., 2002). NK cells can also induce tumor cell elimination through death receptor-mediated pathways such as TRAIL and FasL (Johnsen et al., 1999; Lee et al., 1996; Zamai et al., 1998). A recent two-photon microscopy study showed that NK cells infiltrating tumors establish brief cytotoxic interactions with target cells, allowing NK cells to rapidly kill numerous cancer cells (Deguine et al., 2010).

Activated NK cells and $\gamma\delta$ T-cells are also potent producers of numerous cytokines, including IFN- γ , TNF- α , growth factors such as G-CSF and GM-CSF, and numerous chemokines (Vivier et al., 2011). IFN- γ in particular is thought to have powerful anti-tumor activities, such as inducing MHC I expression and sensitizing tumor cells to CD8+ T-cell killing. Gamma/delta T-cells are appreciated as an important source of IFN- γ in subcutaneous tumor transplantation models (Gao et al., 2003), and NK-cell-derived IFN- γ is positively associated with patient survival in some cancers (Menard et al., 2009). TNF- α can have direct cytotoxic activity by triggering caspase 8-mediated apoptosis (Peter and Krammer, 2003). In addition, the combination of IFN- γ and TNF- α can drive tumor cells

into senescence (Braumuller et al., 2013). Thus, cytokines secreted by innate cells can have direct anti-tumor activities. NK cells also modulate activity of other leukocytes, such as dendritic cells and T-cells, through cytokine secretion or various receptor-ligand interactions (Martin-Fontecha et al., 2004; Moretta et al., 2005). Although cooperation between different leukocytes has not been deeply explored in the context of tumor immunology, a recent report suggested that NK-cell-derived IFN- γ polarizes macrophages towards a tumoricidal “M1” state that confers protection from carcinogen-induced sarcomas (O’Sullivan et al., 2012).

Initiation of the effector mechanisms described above requires innate cells to differentiate between normal cells and their transformed counterparts. However, unlike T-cells, innate leukocytes cannot recognize canonical neo-antigens that arise during tumorigenesis. What then is the molecular basis for the recognition and elimination of tumor cells by innate immune cells? Some innate receptors recognize ubiquitous intracellular self ligands, such as nucleic acids, that stimulate responses in certain cancer-associated contexts. Such receptors may be engaged in the context of the abnormal physiology of cancer cells. In contrast, other innate receptors recognize ligands that are displayed primarily by abnormal cells, so-called “induced self ligands”. The remainder of this review will focus on these latter receptors that bind to self-ligands expressed or upregulated preferentially by tumor cells, enabling certain innate cells to respond to tumor cells. We will introduce and examine these germline-encoded receptors, including the activating receptors NKG2D; DNAM; the natural killing receptors NKp30, NKp44, NKp46, and NKp80; the SLAM-family receptors (the activating receptors are summarized in Table 1); and the inhibitory Ly49 receptors (which are expressed in mice) and KIRs (expressed in humans). Next, we will describe the biological processes that lead to tumor cell expression of the ligands for these activating receptors. Particular emphasis will be placed on how pathways intrinsic to the tumorigenesis process itself result in expression of such ligands. Finally, we will discuss immune escape strategies employed by tumors to avoid these mechanisms of elimination by innate cells. While these receptors and ligands are mostly associated with NK cells, the role of other cells involved in these processes will be addressed when relevant.

3. GERMLINE ENCODED RECEPTORS IMPLICATED IN TUMOR SURVEILLANCE

3.1. NKG2D

NKG2D is a lectin-like type 2 transmembrane receptor encoded by gene *Klrk1* (Killer Cell Lectin-like Receptor Subfamily Member 1) located in the NK gene complex (Raulet, 2003). Due to its short intracellular domain, NKG2D cannot transmit activating signals alone (Houchins et al., 1991). Instead, charged residues in the transmembrane region enable NKG2D to pair with the signaling adaptor proteins DAP10 (in humans and mice) and DAP12 (in mice) (Diefenbach et al., 2002; Gilfillan et al., 2002; Rosen et al., 2004; Zompi et al., 2003), which are essential for NKG2D surface expression and downstream signaling. Pairing with DAP12 occurs only with a specific splice isoform of NKG2D that is present in activated but not resting mouse NK cells (Diefenbach et al., 2002). DAP10 recruits the p85 subunit of phosphoinositide 3-kinase (PI3K) and growth factor receptor-bound protein 2

(GRB2) (Sutherland et al., 2002; Wu et al., 1999), while DAP12 carries an immunoreceptor tyrosine-based activation motif (ITAM) for the recruitment of spleen tyrosine kinase (SYK) and ζ -chain-associated protein kinase 70 (ZAP70) (Zompi et al., 2003). NKG2D engagement leads to downstream activation of PI3K and GRB2, and, in activated mouse NK cells, SYK and ZAP70. These signaling molecules stimulate killing, cytokine production, immune cell activation, and proliferation.

NKG2D is expressed on almost all NK cells, certain CD8⁺ T cells, $\gamma\delta$ T cells, NKT cells, and certain CD4⁺ T cells. In humans NKG2D is expressed by all CD8⁺ T cells and certain activated CD4⁺ T cells, whereas in mice NKG2D is expressed by activated CD8⁺ T cells and has not been documented on conventional CD4⁺ T cells. NKG2D recognizes several MHC-related ligands that are poorly expressed by normal cells and tissues but were shown to be upregulated on various tumor cells in early studies (Bauer et al., 1999; Cerwenka et al., 2000; Diefenbach et al., 2000; Guerra et al., 2008). In the mouse, NKG2D ligands include the family of retinoic acid early inducible-1 proteins (RAE-1 α - ϵ), murine UL16-binding protein like transcript-1 (MULT-1) and the H60 family (H60a, H60b and H60c) of proteins. In humans, NKG2D ligands include UL16-binding proteins (ULBP1-6) and MHC class I-chain-related proteins A and B (MICA and MICB). There is ample evidence that NKG2D ligands are expressed in many human tumors, including melanoma, leukemia, myeloma, glioma, and carcinomas of the prostate, breast, lung and colon (Frieze et al., 2003; Salih et al., 2003; Vetter et al., 2002; Watson et al., 2006). Accumulating evidence shows that the expression of NKG2D is crucial for tumor cell elimination both in vitro and in tumor transplantation experiments in vivo (Bauer et al., 1999; Cerwenka, Baron and Lanier, 2001; Diefenbach et al., 2001). Conflicting results have been obtained using the MCA-induced sarcoma model regarding the role of NKG2D. It was reported that NKG2D antibody blockade increased the incidence of MCA-induced tumors, but no increase was seen in NKG2D KO mice (Crowe, Smyth and Godfrey, 2002; Guerra et al., 2008). The best evidence for the importance of NKG2D comes from experiments using NKG2D KO mice, which were crossed to mice expressing transgenic oncogenes. In the TRAMP model of prostate cancer, the incidence of aggressive adenocarcinoma was increased in the absence of NKG2D. Similarly, in the E μ -Myc model of B cell lymphoma/leukemia, tumor development was markedly accelerated (Guerra et al., 2008).

3.2. Other natural cytotoxicity receptors

In addition to NKG2D, several other NK cell receptors are thought to play roles in tumor cell recognition. Three examples of such receptors, NKp46 (NCR1, CD335), NKp44 (NCR2, CD336) and NKp30 (NCR3, CD337), have been termed “natural cytotoxicity receptors (NCRs)”, though their role in natural killing is no greater than the role of NKG2D. NKp46 and NKp30 are expressed on both resting and activated human NK cells, whereas NKp44 is expressed only on activated human NK cells. In mice, NKp46 has been characterized in some detail, but NKp44 is not present in mice and NKp30 is a pseudogene.

These receptors, when engaged, each trigger NK cell-mediated killing and secretion of IFN- γ . NCRs belong to the immunoglobulin (Ig) super-family of receptors (Cantoni et al., 1999; Pende et al., 1999; Pessino et al., 1998; Sivori et al., 1997; Vitale et al., 1998), have

extracellular Ig domains, and associate non-covalently with adaptor proteins like DAP12 (NKp44), FcεRIγ-CD3ζ (NKp46) and CD3ζ-CD3ζ or CD3ζ-FcεRIγ (NKp30) (Moretta et al., 2001). These adaptor proteins contain ITAMs to recruit and activate the SYK and ZAP70). These kinases phosphorylate transmembrane adaptors such as Linker for the Activation of T cells (LAT) and NTAL (Non-T cell Activation Linker), resulting in the activation of PI3K, phospholipase C (PLC) and VAV proteins (Billadeau et al., 1998; Cella et al., 2004; Spaggiari et al., 2001; Tassi et al., 2005; Upshaw et al., 2005). The calcium flux resulting from these signaling events leads to cytoskeletal reorganization, cellular cytotoxicity and cytokine secretion, mainly IFN-γ and TNF-α (Cantoni et al., 1999; Pende et al., 1999; Pessino et al., 1998).

In vitro studies have demonstrated roles for all three of these receptors in NK-mediated killing of certain tumor cells and infected cells (Arnon et al., 2004; Costello et al., 2002; Fauriat et al., 2007; Moretta et al., 2001; Pende et al., 1999; Sivori et al., 1999).

The identity of the tumor cell ligands for these receptors is a matter of ongoing research, but candidates have emerged over recent years. B7-H6, a molecule that is expressed on the surface of tumor cells and on TLR-triggered monocytes and neutrophils, was identified as a novel ligand for NKp30 (Brandt et al., 2009; Kaifu et al., 2011). In addition, the nuclear protein BCL2-associated athanogene 6 (BAG-6), also known as BAT3, was also proposed as a cellular ligand for NKp30 and implicated in *in vivo* tumor recognition (Pogge von Strandmann et al., 2007; Simhadri et al., 2008).

Despite much research, the tumor-associated ligand for NKp46 remains unknown. Nevertheless, *in vivo* evidence from NKp46 KO mice suggests that NKp46 can inhibit tumor metastasis (Glasner et al., 2012). Other ligands of both cellular and viral origins have also been reported for one or more of these three receptors, but their role in tumor immunosurveillance is unclear.

3.3. NKp80 (KLRF1)

NKp80 is a C-type-lectin-like homodimeric receptor expressed on human NK cells and CD3⁺CD56⁺ T cells (Welte et al., 2006). The cytoplasmic tail of NKp80 contains atypical tyrosine based motifs called hemITAMs that activate the SYK-kinase pathway and trigger NKp80-mediated cytotoxicity (Dennehy, Klimosch and Steinle, 2011; Ruckrich and Steinle, 2013). The receptor ligates Activation-Induced C-type Lectin (AICL), an activating receptor preferentially expressed by myeloid cells (Welte et al., 2006). The AICL-Nkp80 interaction stimulates NK cytotoxicity, and plays a role in the recognition of myeloid tumor cells (Welte et al., 2006).

3.4. SLAM-related Receptors

The SLAM (Signaling Lymphocyte Activating Molecule)-related receptors are expressed on a wide variety of immune cells including NK cells, monocytes/macrophages, mast cells, granulocytes, γδ T cells, DCs, and CD8⁺ T cells (Veillette, 2006). The family includes the SLAM (CD150), 2B4 (CD244), NTB-A (Ly108), CD84, Ly9 (CD229) and CRACC (CD319) receptors (Veillette, 2006). Most SLAM receptors engage in homotypic

interactions with the same protein on another cell, with exception of 2B4 and CD84, which interact with each other. SLAM receptor engagement results in activating signals via the action of several receptor-associated adaptor proteins belonging to the SAP (SLAM-associated protein) family (Veillette, 2006). In the absence of the known SAP family adaptors the SLAM family receptors convey strong inhibitory signals that repress activation caused by other receptors such as NKG2D (Dong et al., 2009; Lee et al., 2004b; McNerney, Guzik and Kumar, 2005; Vaidya et al., 2005). The SLAM receptors play critical roles in NK-mediated killing of hematopoietic target cells, including MHC-deficient normal hematopoietic cells and lymphoma cells, but SLAM receptors are dispensable for recognition of non-hematopoietic tumor cells (Dong et al., 2009). NK cells from SAP-deficient humans and mice have a reduced ability to kill hematopoietic target cells (Benoit et al., 2000; Bloch-Queyrat et al., 2005; Nakajima et al., 2000; Tangye et al., 2000).

3.5. Adhesion molecules and DNAM-1

In adhering to target cells, NK cells create an immunological synapse where activating and inhibitory receptors spatially cluster in order to increase the efficacy of intracellular signaling. Adhesion molecules such as the integrin LFA-1 play a key role in the formation of immunological synapses (Long et al., 2013; Watzl and Long, 2010). The engagement of LFA-1 with its ligands ICAM-1 or ICAM-2 on target cells results in polarization of cytotoxic granules toward the immunological synapse (Barber, Faure and Long, 2004; Bryceson et al., 2005; Mentlik et al., 2010) and is essential for NK cell and T cell interactions with many target cells.

The Ig-superfamily receptor DNAM-1 (CD226) associates with LFA-1 on the cell surface and potentiates activating signals. LFA-1 engagement results in Fyn kinase-mediated phosphorylation of the DNAM-1 cytoplasmic domain (Shibuya et al., 1999; Shibuya et al., 2003). DNAM-1 is expressed by a variety of leukocytes such as NK cells, T cells, B cells, monocytes, and platelets (Burns et al., 1985; Scott et al., 1989; Shibuya et al., 1996). Patients with Leukocyte Adhesion Deficiency (LAD) lack LFA-1 and are unresponsive to stimulation with DNAM-1 ligands (Shibuya et al., 1999).

Two ligands for DNAM-1 have been identified in humans and mice: PVR (CD155), a member of the Nectin family of proteins, and Nectin-2 (CD112), a member of the Nectin-like family (Bottino et al., 2003; Tahara-Hanaoka et al., 2004). Nectin-2 and PVR are broadly distributed on many tissues throughout the body, including neurons, epithelial cells, endothelial cells and fibroblasts (Fuchs and Colonna, 2006). PVR can also be bound by the receptors TACTILE and TIGIT, but the roles of those receptors in immunosurveillance have not been characterized (Fuchs et al., 2004; Stanietsky et al., 2013). DNAM-1 ligands are frequently expressed by tumor cells (Bottino et al., 2003; Masson et al., 2001; Sloan et al., 2004; Tahara-Hanaoka et al., 2004), and the interaction is in some cases essential for normal triggering of NK cell-mediated cytotoxicity and cytokine production (Bottino et al., 2003; Burns et al., 1985; Lakshmikanth et al., 2009; Shibuya et al., 1996). NK cell killing of neuroblastoma cells from different patients was well-correlated with the expression of DNAM-1 ligands on the tumor cells (Castriconi et al., 2004). However, DNAM-1 engagement is not sufficient to induce target cell killing, but synergistically activates NK

cells that are also stimulated via the 2B4, NKp46 and possibly other receptors (Bryceson et al., 2005; Bryceson et al., 2006).

Notably, *Dnam1*^{-/-} mice had accelerated growth of fibrosarcomas and papillomas in response to chemical carcinogens as well as reduced rejection of transplanted tumor cells expressing DNAM-1 ligands (Gilfillan et al., 2008; Iguchi-Manaka et al., 2008). These findings suggest a significant role of DNAM-1 in tumor immunosurveillance.

3.6. MHC-specific NK cell inhibitory receptors

NK cells express a variety of receptors that transmit inhibitory signals when engaged by MHC I molecules expressed by target cells. These include the Ly49 and KIR families of receptors that recognize MHC class Ia molecules directly. Mice express Ly49 receptors but not KIRs, whereas humans express KIRs but not Ly49 receptors. A third, shared, inhibitory receptor is the CD94/NKG2A heterodimeric receptor, which recognizes a peptide derived from the class Ia leader sequence presented by a specific nonclassical MHC I molecule (HLA-E in humans and Qa-1 in mice) (Braud et al., 1998; Lee et al., 1998; Vance et al., 1998). Inhibitory receptors signal through immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their cytoplasmic tails. Upon receptor engagement, ITIMs are tyrosine-phosphorylated and recruit the protein tyrosine phosphatases SHP-1 and SHP-2 (Lanier, 1998; Long, 1999; Ravetch and Lanier, 2000). The phosphatases are believed to inhibit activation by dephosphorylating one or more critical signaling molecules, especially VAV-1 (Binstadt et al., 1996; Burshtyn et al., 1996; Campbell et al., 1996; Olcese et al., 1996).

Each KIR, Ly49 or CD94/NKG2A receptor is expressed on only a fraction of NK cells, such that the resulting NK repertoire allows for recognition of host cells that have lost just a single class Ia allele (Moretta et al., 1996; Raulet, Vance and McMahon, 2001; Shilling et al., 2002). Because selective loss of class I MHC expression is a common feature of many tumor cells (Garrido et al., 1997), the diverse KIR expression by NK cells allows for recognition and elimination of tumor cells or other cells that have such alterations in MHC I expression. The recognition and destruction of cells lacking MHC I is called “missing self recognition” (Ljunggren and Karre, 1990).

Missing self recognition was discovered in studies showing that RMA-S, a lymphoma cell line selected for loss of MHC I expression, was sensitive to NK cells while RMA cells, an MHC+ counterpart to RMA-S was not (Karre et al., 1986). Later studies showed that even normal cells lacking MHC I are destroyed by NK cells (Bix et al., 1991). The absence of MHC I molecules by RMA-S cells or MHC I-deficient normal cells is not a sufficient condition for destruction of the cells, as the susceptible cells must also express ligands that activate NK cells, albeit weakly. Recent evidence suggests that such killing does require engagement of specific activating receptors on NK cells, namely the SLAM family receptors (Dong et al., 2009). This conclusion is based in part on the finding that NK cells lacking the SAP family adapters for SLAM receptors were unable to kill MHC-deficient normal cells or RMA-S cells in vivo or in vitro. Notably, the SLAM proteins, which also serve as ligands for SLAM receptors, are restricted in expression to hematopoietic cells. Signals provided by SLAM receptor engagement are insufficient to override inhibition imparted by MHC I-

specific receptors, explaining why normal MHC+ cells are not susceptible to NK-mediated killing.

4. THE IMMUNOGENICITY OF CANCER: HOW ALTERATIONS COMMON TO CANCER CAN RESULT IN DETECTION BY INNATE IMMUNE CELLS

4.1. Proliferation

Dysregulated proliferation is a hallmark of cancer. Mutations of proto-oncogenes that promote cell cycle progression, coupled with insensitivity to growth inhibition, can cause transformed cells to proliferate in an uncontrolled manner (Hanahan and Weinberg, 2000).

Many cell-intrinsic mechanisms can sense excessive proliferation. For example, oncogenic mutations that constitutively activate the RAS, PI3K and/or MAPK pathways, central drivers of cell growth and proliferation, can activate tumor suppressor proteins such as p53. Activation of p53 can mediate temporary growth arrest, permanent inhibition of cell cycle progression (senescence), or programmed cell death (Vousden and Prives, 2009). Activation of the RAS pathway has recently been shown to upregulate expression of the RAE1 proteins in mice, and ULBP1-3 in human cells (Liu et al., 2012). In that study induction of NKG2D ligands depended on RAF, MAPK/MEK, and PI3K, but not ATM or ATR. Interestingly, activation of the PI3K pathway has also been linked to induction of RAE-1 ligands in MCMV infection and in various tumor cell lines (Tokuyama et al., 2011).

Recent evidence suggests that proliferation is also coupled to cell-extrinsic tumor suppressive pathways mediated by immune cells that express NKG2D. Primary mouse fibroblasts cultured ex vivo were shown to spontaneously upregulate the NKG2D ligand RAE-1 and acquire sensitivity to killing by NK cells that was NKG2D-dependent (Jung et al., 2012). RAE-1 induction was blocked by inhibition of cyclin-dependent kinases (Roscovitine), the PI3K-mTOR pathway (LY294002, Rapamycin), and the MAPK pathway (SB202190). Cells cultured in serum-limiting conditions showed a delayed and reduced induction of RAE-1, and cells cultured in high serum concentrations (and thus displaying high RAE-1 levels) rapidly downregulated RAE-1 expression upon serum starvation. Furthermore, when cells were serum-starved and subsequently cultured in the presence of serum, only the cells that re-entered the cell cycle (as demonstrated by BrdU incorporation) upregulated RAE-1. Addition of recombinant epidermal growth factor to serum-free media was sufficient to rescue proliferation and RAE-1 expression.

RAE-1 expression on a variety of mouse and human tumor cell lines was dependent on proliferation, as serum starvation or CDK inhibition reduced cell surface RAE-1 levels (Jung et al., 2012). Interestingly, certain untransformed cells undergoing rapid proliferation, such as early embryonic brain cells and cells proliferating in healing skin wounds, were found to express RAE-1 in vivo (Jung et al., 2012). Earlier studies showed that proliferating human T-cells upregulate NKG2D ligands (Zingoni et al., 2012), and several reports have described constitutive NKG2D ligand expression in subpopulations of cells in rapidly proliferating tissues such as the bone marrow (Ogasawara et al., 2005) and intestinal epithelium (Groh et al., 1996). On the other hand, proliferation is frequently insufficient to result in substantial upregulation of NKG2D ligands. For example, little or no upregulation was observed in

mouse T and B cells stimulated with mitogens in vitro (Diefenbach et al., 2000), or in brain cells in the late embryonic period, where cells are proliferating at a slower rate than at earlier stages of development (Jung et al., 2012). In those cases, expression of NKG2D ligands may require a faster rate of cell proliferation or cooperation with other signals.

In primary fibroblasts, the molecular link between proliferation and RAE-1 expression was found to depend on the E2F family of transcription factors (Jung et al., 2012). E2F proteins transactivate expression of numerous cell-cycle-associated genes, and E2F activity is tightly regulated by a variety of transcriptional and post-translational mechanisms. E2F proteins bound to sites in the *Raet1e* promoter in proliferating cells, but much less so in serum-starved cells. E2F overexpression was sufficient to activate endogenous *Raet1* genes in cells as well as a luciferase reporter construct driven by the *Raet1e* promoter (Jung et al., 2012). Neither the DNA damage response nor p53 were found to be involved in RAE-1 expression in proliferating primary cultures of fibroblasts (Jung et al., 2012).

This connection between proliferation and NKG2D ligand expression provides evidence of a compelling link between an inherent characteristic of cancer and cell-extrinsic tumor suppressor activities mediated by immune cells. It will be important to further investigate tumor cell proliferation and NKG2D ligand expression in primary cancer models, to understand the role of NKG2D ligand expression on normal proliferating cells, and to uncover why some proliferating cells but not others express these ligands. As discussed elsewhere in this review, other mechanisms associated with aberrant cell cycle progression, such as p53 activation, may enhance tumor-suppression by immune cells by independent mechanisms.

4.2. Role of the DNA damage response

Replication stress (the result of stalled replication forks) and DNA double-strand breaks activate the DNA damage response (DDR) in tumor cells and precancerous lesions (Bartkova et al., 2005; Gorgoulis et al., 2005). DNA damage and replication stress activate the protein kinases ATR and/or ATM, which initiate the DDR kinase cascade (Cimprich and Cortez, 2008; Shiloh and Ziv, 2013) by phosphorylating the checkpoint kinases CHK1 and CHK2, respectively, in addition to many other target proteins. Activation of the DDR arrests cell cycle progression, and induces DNA repair functions. If DNA damage is extensive or irreparable, the DDR activates the p53 tumor suppressor, which can induce apoptosis or senescence depending on the cellular context. The DDR is often activated in developing tumors, but is also induced by many common cancer therapies, including irradiation and many chemotherapeutic drugs (Lord and Ashworth, 2012).

In response to DNA damage, the mouse NKG2D ligands RAE-1 and MULT1 (Gasser et al., 2005; Gasser and Raulet, 2006) and the human NKG2D ligands ULBP1-3 and MICA/B (Gasser et al., 2005; Soriani et al., 2009) are upregulated, although which ligand(s) and the degree of upregulation varies between different cell types and patient samples. Expression of DNAM-1 ligands also increases in response to DDR activation (Ardolino et al., 2011; Soriani et al., 2009). In the studies cited above, upregulation of ligands for both NKG2D and DNAM-1 in response to DNA damage occurred in an ATR/ATM- and CHK1/CHK2-dependent manner. The in vivo relevance of these findings is suggested by recent evidence

that spontaneous tumor regression in the *Eμ-Myc* transgenic model of lymphoma/leukemia is partially ATM and DNAM-1 dependent (Croxford et al., 2013).

Although NKG2D ligand mRNA levels increase in response to DNA damage, the rate of transcription of these genes did not increase in nuclear run-on experiments, whereas the rate of degradation of the *Raet1* mRNA was decreased, suggesting that the DDR drives stabilization of NKG2D ligand mRNAs rather than transcription of the ligand genes (B. Hsiung and D.H. Raulet, unpublished data). The mechanism of transcript stabilization remains unclear. DDR-mediated increases in DNAM-1 ligand expression also occur at the mRNA level, but the specific mechanism has not been investigated to date. It is also unknown whether NKG2D and DNAM-1 ligands are controlled by the same or different DDR effectors.

Activation of the tumor suppressor p53 is a major downstream effect of the DDR, but NKG2D ligand upregulation in response to DNA damage was p53-independent in the mouse studies performed to date (Gasser et al., 2005; Iannello et al., 2013). In human cells, however, two different studies suggested that p53 stimulates transcription of certain NKG2D ligands. It was reported that preventing proteasomal degradation of p53 by the MDM2 inhibitors RITA and Nutlin allows p53 to bind the promoter region of the *ULBP1* and *ULBP2* genes, resulting in enhanced *ULBP1* expression (Li et al., 2011; Textor et al., 2011). Surprisingly, another study concluded that p53 activation negatively regulates human NKG2D ligand expression (Heinemann et al., 2012). Notably, neither of these effects of p53 were studied in the context of the DNA damage response.

4.3. Role of oncogene-induced senescence in innate responses against tumor cells

p53 plays a central role in regulating various cell-intrinsic biological processes including apoptosis, DNA repair and the induction of cellular senescence. By limiting cell proliferation, cellular senescence represents an intrinsic barrier to tumorigenesis (Braig and Schmitt, 2006; Collado and Serrano, 2010). The two major types of cellular senescence are replicative senescence, which is linked to telomere shortening occurring in normally dividing cells, and oncogene-induced senescence (OIS), which is associated with oncogene activation (Collado and Serrano, 2010; Stewart and Weinberg, 2006). Activation of p53/p21 and p16/Rb tumor suppressor pathways during oncogenic stress can trigger senescence. Interestingly, a recent study suggested that adaptive CD4⁺ T cell-mediated immune responses against tumors can also induce a senescent state through the secretion of TNF-α and IFN-γ, expanding the array of effector mechanisms that lymphocytes employ to inhibit tumor progression (Braumuller et al., 2013).

The link between cellular senescence and innate immune responses has been investigated in several contexts. One study showed that elimination of tumor cells, rendered senescent as a result of induction of p53, was mediated by NK cells, macrophages and neutrophils (Xue et al., 2007), whereas another study determined that senescence was associated with adaptive (CD4 cell-mediated) responses against tumor cells (Kang et al., 2011). Yet another study concluded that immune-mediated removal of senescent cells resulting from fibrotic injury was essential for resolution of the injury (Krizhanovsky et al., 2008).

A recent study investigated how p53 activation and the accompanying senescence enable NK cells to eliminate senescent tumor cells (Iannello et al., 2013). First, it was shown that NK-mediated elimination of mouse hepatocellular carcinoma cells, rendered senescent by induction of p53 in growing tumors, was nearly entirely dependent on NKG2D-mediated recognition of RAE-1 ligands displayed on the senescent tumor cells. Interestingly, however, RAE-1 expression was not dependent on p53 expression, as it was already high on growing tumor cells. In seeking an explanation for why the NK cells failed to eliminate RAE-1-expressing nonsenescent tumor cells, it was noted that very few NK cells infiltrated such growing tumors, whereas many NK cells infiltrated senescent tumor cells in which p53-expression had been induced. NK cell infiltration occurred in NKG2D knockout mice and so was independent of NKG2D signaling. Analysis revealed that p53 restoration substantially increased tumor cell production of numerous chemokines known to recruit NK cells and other immune cells, including CCL2, CCL3, CCL4, CCL5, CXCL1 and CXCL2. Indeed, it has been previously established that senescent cells exhibit the “senescence-associated secretory phenotype” (SASP), which is characterized by secretion of numerous soluble factors including chemokines (Campisi, 2012; Tchkonja et al., 2013). Neutralization of CCL2 in vivo with antibodies caused a dramatic reduction in NK cell accumulation in tumor cells, whereas neutralization of CCL3, CCL4 and CCL5 had no effect (Iannello et al., 2013). Furthermore, CCL2 neutralization, but not neutralization of the other chemokines, resulted in delayed elimination of the senescent tumor cells, providing direct evidence that p53-induced CCL2 expression was responsible for NK cell recruitment and senescent tumor elimination. An interesting implication of these findings was that tumor elimination depended on the cooperation of two independently regulated features of the tumor cells: chemokine production, which was p53-dependent, and RAE-1 expression, which was independent of p53 and likely regulated by the pathways discussed in detail earlier in this review.

5. INTERPLAY BETWEEN TUMORS AND INNATE LYMPHOCYTES

The accumulation of studies showing roles in tumor surveillance for the immune system raise important questions, such as why tumors progress despite such surveillance. In the following sections, some findings pertinent to this question will be reviewed.

5.1. Selective loss of NK-activating ligands associated with evasion of innate immune surveillance

In studies of T cell mediated anti-tumor responses, it has become clear that tumors evolve under the selective influences of the immune response. One line of evidence for such selection is that tumors that arise in immune-deficient animals grow progressively if transferred to a similarly immune-deficient host, but tend to be rejected if transferred to wildtype mice (Shankaran et al., 2001). In some cases, specific mutations accumulate in tumor cells that eliminate epitopes that T cells would otherwise recognize (Matsushita et al., 2012). This phenomenon has been termed “cancer immunoediting” (Dunn, Old and Schreiber, 2004; Schreiber, Old and Smyth, 2011) and provides a distinct line of evidence for immune surveillance of tumors, and at the same time delineates one mechanism of how immune surveillance is overcome.

Evidence for immunoediting has also been provided in the case of innate responses against cancer. In the TRAMP transgenic model of prostate adenocarcinoma, aggressive tumors that arose in wildtype mice lacked NKG2D ligands on the cell surface, whereas similar tumors that arose in NKG2D-deficient littermates uniformly expressed one or more NKG2D ligand (Guerra et al., 2008). These data suggested that tumors detected in mice that express NKG2D had been selected for loss of NKG2D ligands. Considering the reduced number of aggressive tumors in these NKG2D-expressing mice, and the absence of ligands on such tumors, it was proposed that NKG2D-dependent immune selection eliminates a majority of newly arising aggressive tumors, but that another fraction of tumors persists because variant cells within those tumors extinguish ligand expression and are therefore able to evade immune detection (Guerra et al., 2008).

Selection for loss of NKG2D ligands does not occur in all cancer models. In the *Eμ-myc* model of B lymphoma, for example, tumors that arose in mice expressing NKG2D did not lack NKG2D ligands, despite the fact that tumorigenesis was delayed in those mice (Guerra et al., 2008). It is not known why such tumors are refractory to selection by NKG2D whereas others are not, but one speculation is that certain types of tumors evolve mechanisms to dominantly inactivate NK cells or other relevant effector cells, and therefore can evade the response without extinguishing NKG2D ligands.

Demonstrating immuno-editing resulting from other modes of NK cell recognition is more difficult because the relevant ligands have not been identified for most of the other NK receptors. One study attempted to detect a role for the NKp46 activating receptor in surveillance of MCA-induced fibrosarcomas by comparing tumor incidence and phenotype in NKp46 mutant versus wildtype mice. The incidence of tumors was not different, but tumors arising in NKp46-deficient mice stained with an NKp46-Ig fusion protein, suggesting they expressed NKp46 ligands, whereas tumors arising in wildtype mice did not (Elboim et al., 2010). Furthermore, when cell lines derived from these tumors were injected into mice, it was observed that tumors that arose in the absence of NKp46 grew more slowly than tumors that originated from wildtype mice. On the basis of these findings, it was concluded that tumors readily undergo selection for loss of NKp46 ligands.

5.2. Ligand shedding as a mechanism of evasion

Many tumor cell lines release soluble NKG2D ligands through a variety of mechanisms, including alternative splicing, PI-PLC-mediated cleavage, proteolytic shedding, or exosome secretion (reviewed in more detail in (Chitadze et al., 2013; Raulet et al., 2013)). Indeed, soluble MIC and ULBP proteins have been identified in the sera of patients with various tumor types including breast, lung, colon, and ovarian carcinoma, glioma, neuroblastoma, leukemia, and melanoma (Boissel et al., 2006; Doubrovina et al., 2003; Groh et al., 2002; Jinushi et al., 2005; Marten et al., 2006; Salih, Goehlsdorf and Steinle, 2006; Salih, Rammensee and Steinle, 2002). In the mouse, both RAE-1 (Champsaur and Lanier, 2010) and MULT1 (W. Deng & D.H. Raulet, unpublished data) ligands have been detected in soluble form in cell culture supernatants. The presence of soluble ligands in the sera of cancer patients may in some cases serve as prognostic indicators of cancer. For example, the level of soluble ULBP2 was shown to discriminate patients at an early stage of pancreatic

adenocarcinoma from healthy donors (Chang et al., 2011) and to identify melanoma patients at risk for disease progression (Paschen et al., 2009). Furthermore, increased serum concentrations of soluble ULBP2 were associated with a poorer prognosis in patients with early-stage B cell chronic lymphocytic leukemia (Nuckel et al., 2010).

Depending on the specific setting and the nature of the excreted ligands, the various forms of soluble NKG2D ligands can potentially exert distinct effects on NKG2D/NKG2D ligand interactions. Shedding of NKG2D ligands from tumor cells can result in dramatically lower cell surface levels, reducing their susceptibility to cytotoxicity by NK cells and T cells. At the same time, the accumulated shed ligands may interact with NKG2D on the surface of NK cells and T cells, even those at a distance from the primary tumor (Chauveau et al., 2010). Binding of the soluble ligands may prevent interactions of NKG2D with membrane-bound ligands. Alternatively, if the soluble ligands can transmit signals through NKG2D, these interactions have the potential to either activate or desensitize the NK cells or T cells. Indeed, rather than inhibiting NK activity, NKG2D ligand-containing exosomes derived from human DCs were reported to directly activate human NK cells *ex vivo* (Viaud et al., 2009). Presumably, the capacity of ligand-containing exosomes to crosslink NKG2D can explain the activating effect of the exosomes.

Soluble NKG2D ligands are also thought to impair immune surveillance by modulating NKG2D expression. In some cases, for example, cancer patients with elevated soluble MICA in their serum exhibited strongly reduced NKG2D staining of their peripheral blood CD8⁺ T cells (Groh et al., 2002). Similarly, soluble ULBP1-3 were found to downregulate NKG2D on NK cells (Fernandez-Messina et al., 2010; Song et al., 2006). Notably, however, a functional impact of soluble NKG2D ligands was not always observed (von Lilienfeld-Toal et al., 2010). For example, the sera from MICA transgenic mice, which contained high levels of soluble MICA, had only a marginal effect on NKG2D surface expression on non-transgenic NK cells (Wiemann et al., 2005). In addition, no inhibitory effects on NKG2D expression were observed with supernatants containing soluble MULT1, a mouse NKG2D ligand (W. Deng & D. H. Raulet, unpublished data). Also of concern is that in most studies, the form of the ligands (exosomes versus enzymatically shed molecules) was not determined.

In a few studies, the role of soluble NKG2D ligands was examined by attempting to neutralize the soluble ligands with anti-MICA antibody (Wang et al., 2008) or NKG2D-Fc fusion proteins (Hilpert et al., 2012). Those studies suggested a correlation between elevated soluble NKG2D ligand levels in specific tumor patients and reduced NKG2D-dependent immune responses, but the generality of these findings and the specific mechanisms responsible remain unclear. Serum from tumor patients contains many additional immunosuppressive factors (e.g., TGF- β) which reportedly downregulate NKG2D. For example, despite the presence of soluble NKG2D ligands in the sera of glioblastoma patients, NKG2D downregulation was primarily caused by tumor-derived TGF- β (Lee et al., 2004a). Another point of concern is that exosomes may “bundle” a variety of tumor-derived ligands of other molecules, which may have to act together to impact NK and T cell immune responses.

5.3. Evasion of NK-cell mediated immunosurveillance as a result of anergy of NK cells

As already mentioned, in some cases tumors develop without losing expression of immune-activating ligands. While the underlying mechanisms for this outcome remains unclear, it is known that chronic engagement of activating receptors can lead to immune dysfunction. *In vitro* experiments showed that chronic engagement of NK cells with cells expressing NKG2D ligands substantially diminishes the function of the NK cells, even affecting responses mediated through receptors other than NKG2D (Coudert et al., 2008; Coudert et al., 2005). In the case of a transgenic mouse strain expressing RAE-1 constitutively, the NK cells exhibited lower activity against cells with NKG2D ligands but also were less effective at rejecting MHC-deficient cells that lack NKG2D ligands, suggesting a general dysfunction of the cells (Oppenheim et al., 2005). Although this finding was not confirmed with a distinct RAE-1 transgenic line, which may express lower levels of RAE-1 (Champsaur et al., 2010), a similar general functional defect was observed in mice that constitutively expressed the viral protein m157, which binds the Ly49H activating receptor (Sun and Lanier, 2008). Although it has not been investigated directly, these findings raise the possibility that in some cases tumors expressing activating ligands, such as NKG2D ligands, may induce anergy or hyporesponsiveness of NK cells, enabling the tumors to evade immune surveillance.

A recent study addressed whether there are conditions in which NK cells within MHC-deficient lymphoma cells are rendered anergic to the tumor cells, a pertinent question since many tumor cells lack MHC I (Garrido and Algarra, 2001), and NK cells in cancer patients often display functional defects (Costello et al., 2002; Epling-Burnette et al., 2007; Fauriat et al., 2005). It was shown that when the capacity of NK cells to reject MHC I-deficient tumor cells was overwhelmed by the inoculation of a large dose of MHC I-deficient lymphoma cells (RMA-S cells), NK cells were recruited to the tumor but were rendered hyporesponsive. These NK cells showed reduced responses when stimulated by heterologous tumor cells or other stimuli. In contrast, NK cells infiltrating tumors formed with the same dose of RMA cells, the MHC I+ counterpart line of RMA-S cells, were fully responsive. RMA-S cells in which MHC expression was restored also failed to induce hyporesponsiveness, confirming the importance of MHC-deficiency. These findings suggest that sustained stimulation by MHC-deficient tumor cells results in the induction of a functionally anergic phenotype in NK cells infiltrating and residing within the tumor bed. Interestingly, *in vivo* administration to tumor-bearing animals of pro-inflammatory cytokines, such as IL-12 and IL-18, reversed the functional anergy of the NK cells, and increased the survival of the mice. The potential significance of these findings is that they suggest a likely mechanism of immune evasion. When the capacity of NK cells to mediate tumor rejection is overwhelmed, perhaps because the tumor is well advanced at the time that it is infiltrated, the persistent stimulation of the NK cells drives them into a hyporesponsive state.

6. CONCLUDING REMARKS

As discussed in the preceding pages, evidence from knockout mice and antibody depletion studies suggest a role for innate components, including NK cells and various germline

receptors, in immune surveillance in both carcinogen-induced and genetic models of cancer. Table 2 summarizes the various ways NK cells can be activated during tumor development. Complementary data show that tumors that arise in wildtype mice often contain alterations that are absent in mice lacking innate components, suggesting that the innate response plays an active role in selecting variant, resistant tumors, a process that has been termed immuno-editing.

NKG2D and DNAM-1 ligands can be induced by proliferation (Ardolino et al., 2011; Jung et al., 2012) and by the DNA damage response (Ardolino et al., 2011; Gasser et al., 2005), and it has been suggested that DNAM-1 ligands play roles in cancer invasion and metastasis (Sloan et al., 2004). In addition to the expression of cell surface ligands, soluble factors such as cytokines and chemokines may also play a role in activating the immune system (Iannello et al., 2013; O'Sullivan et al., 2012). Some of these processes are considered 'hallmarks of cancer' (Hanahan and Weinberg, 2011), supporting the proposal that malignant transformation is coupled to events that render cells immunogenic. In the future, it will be of interest to explore the role of other aspects of tumorigenesis in the immunogenicity of cancer cells.

Some of the pathways in tumor cells that control NK ligands and other aspects of immunogenicity are active in normal cells as well. This consideration prompts the question: can tumor cells be reliably distinguished from normal cells by these mechanisms? Are the pathways that support induction of NK activating ligands sufficiently specific to prevent the destruction of normal cells? As an obvious example, cellular proliferation is presumably insufficiently specific as a basis for immunogenicity of cancer cells.

Multiple mechanisms and processes are likely to explain the specificity of the NK response in different contexts. First, cellular proliferation is not sufficient for ligand induction in all cell types, such as activated mouse T cells (Diefenbach et al., 2000), possibly due to a specific genetic repression of the ligand genes; this would ensure that those cells are not inadvertently destroyed. In some cell types, it is likely that multiple pathways must cooperate to support high-level expression of the ligands. As discussed, the regulation of ligands at distinct levels of biogenesis (transcription, translation, protein and mRNA stabilization) by different dysregulated pathways, may explain why cells sustain high expression of activating ligands only in unhealthy cells. In other cases, efficient activation of NK cells, especially resting NK cells, is thought to depend on simultaneous engagement of multiple activating or accessory receptors. Hence, induction of ligands for one NK receptor may not always be sufficient to stimulate an active NK response. Yet another important consideration is that induction of NK activating ligands on certain cells will have little effect if NK cells are not recruited to the vicinity of those cells, as previously discussed in the case of senescent vs. non-senescent tumors. In that instance, mobilization of an independent pathway is necessary to cause chemokine production and NK cell recruitment. A requirement for immune cell recruitment is likely to provide an added level of specificity to innate responses in other contexts as well.

It is interesting to speculate on the evolutionary basis of innate anti-tumor responses and their relationship to anti-pathogen responses. In light of the fact that these cells, receptors

and ligands participate in both anti-pathogen and anti-tumor responses, a relevant but difficult question is whether one or the other form of selection (infection versus cancer) played the greater role in the initial appearance of a cell type or receptor-ligand system. It is commonly asserted that the predominance of cancer late in life means that selective pressures for anti-tumor immune mechanisms would come at a post-reproductive age and therefore be ineffective. Assumptions as to the timing in the life cycle, or source, of selective pressures that acted on organisms when these mechanisms evolved are full of uncertainties, however. Moreover, a counter argument is that cancer is delayed in life because of tumor suppressor mechanisms, including immune-mediated mechanisms, which would act in concert with cell-intrinsic tumor suppressive mechanisms such as p53 and PTEN. Regardless of the types of selection present during the early evolution of these cells and their recognition systems, selective pressures are likely to have adapted the cells or their receptor systems for additional purposes. The fact that common stress pathways involved in NK-cell activating ligand expression are activated in both infected and transformed cells is consistent with this notion.

There are several potential benefits to using the immune system to control tumors, which in some cases have advantages compared to cell-intrinsic mechanisms. First, cell-intrinsic mechanisms, like any other mechanism, are prone to failure, necessitating the existence of redundant systems. A second, unique, benefit of immune mechanisms of tumor suppression is that they can act in a paracrine manner. Secretion of cytokines such as IFN- γ , for example, can suppress the growth of neighboring tumor cells even if they do not upregulate immune-activating ligands. The importance of this concept is suggested by the documented prevalence of cellular heterogeneity in tumors (Navin et al., 2011). Third, activation of innate immunity, including NK cells, can promote tumor-specific adaptive immune responses that can provide dominant and systemic protection and long-lasting memory. It must be emphasized that separately assessing the benefits of intrinsic and immune-mediated tumor suppression mechanisms is complicated by the fact that in some cases they act cooperatively. An example is the induction by p53 of immune-mediated anti-tumor mechanisms, such as chemokine production that attracts NK cells to tumors. Notably, the mobilization of immune responses by intrinsic tumor suppressors confers the same advantage just mentioned with respect to IFN- γ production: even if only a fraction of tumor cells express p53, the attracted NK cells may nevertheless kill the p53-deficient tumor cells.

The two main pathways that allow tumors to escape the immune system are loss of immunogenic determinants and the tumor-driven suppression or desensitization of the immune response. Loss of immunogenic determinants can occur at the genetic level (deletion or mutation of a gene), epigenetic level (silencing of a gene), or at the post-translational level. Active suppression of the immune response can occur through expression of immune inhibiting molecules at the cell surface (such as PD-L1/2 (Hirano et al., 2005)) or secretion of immunosuppressive cytokines (such as TGF- β (Eisele et al., 2006)). An example of desensitization of the immune response is the chronic stimulation of the immune system by immunogenic tumors, which can eventually lead to anergy and immune dysfunction, and which may occur in NK cells in the tumor microenvironment (Coudert et al., 2008; Oppenheim et al., 2005). Some of the ways tumors can escape elimination by NK cells are summarized in Table 3.

Reversing these defects in innate immunosurveillance is an attractive approach for cancer therapy that is receiving much recent attention. Interestingly, conventional chemotherapeutic agents may already have such effects, since they have been reported to induce NKG2D ligands on tumors cells. The relevant drugs can be divided into three broad categories: DNA damaging agents (Cerboni et al., 2009; Gasser et al., 2005), proteasome inhibitors (Hallett et al., 2008), and histone deacetylase inhibitors (Diermayr et al., 2008). Hence, it is possible that some of the therapeutic benefit seen with chemotherapy stems from immune activation rather than a direct cytotoxic effect. Given that tumor cells are already experiencing various stresses, induction of immune-activating ligands may be more likely to occur in these cells as opposed to normal healthy cells.

The scenario in which tumors are not rejected despite expression of immune-activating ligands (such as NKG2D ligands) requires a different therapeutic approach. In these cases the ineffectiveness of the response may be due to shedding of ligands, failure to recruit the appropriate immune cells, or inactivation of the cells once they infiltrate the tumor. In the case of shed ligands, drugs that inhibit shedding or neutralize shed ligands may be effective. In consideration of this possibility an interesting study showed that the presence of naturally arising antibodies to MICA/B are correlated with an improved outcome in multiple myeloma patients (Jinushi et al., 2008). Inhibitory cytokines may be neutralized with by injections of appropriate monoclonal antibodies. The molecular mechanisms of anergy in innate immune cells are not yet known, so it is not yet possible to specify the best approaches to reverse anergy of these cells. Nevertheless, the recent dramatic clinical success of CTLA4 and PD1 antibodies in cancer patients (Hodi et al., 2010; Topalian et al., 2012) make it tempting to speculate that reversing anergy of innate immune cells could also provide significant therapeutic benefit.

Substantial progress has been made over the past decade in elucidating mechanisms underlying the innate immune response to cancer. A big-picture understanding of how tumors progress in the presence of the immune system is still elusive. Cancer genome sequencing studies have identified recurring mutational signatures in various cancers, but the corresponding immunological signatures of tumors have not been extensively studied. Remedying this knowledge gap is likely to be important given that infiltration of immune cells into tumors is correlated with positive prognoses (Coca et al., 1997; Galon et al., 2006). Increased understanding of the complex interactions between cancer and the immune system are likely to lead to improvements in current therapeutic approaches and to spur the development of novel ones.

Acknowledgments

The authors acknowledge grant support from the National Institutes of Health (R01-CA093678 and R01-AI039642 to DHR) and the Prostate Cancer Foundation. Benjamin Gowen is the recipient of the National Science Foundation Graduate Research Fellowship. Thornton Thompson is the recipient of the Cancer Research Institute Student Training in Tumor Immunology Fellowship. Alexandre Iannello is the recipient of the Leukemia and Lymphoma Society Special Fellow award. Lin Wang is the recipient of the Leukemia and Lymphoma Society Fellow award. Michele Ardolino and Weiwen Deng were supported by Cancer Research Institute post-doctoral fellowships.

REFERENCES

- Ames E, Murphy WJ. Advantages and clinical applications of natural killer cells in cancer immunotherapy. *Cancer immunology, immunotherapy* : CII. 2013
- Andre MC, Sigurdardottir D, Kuttruff S, Pommerl B, Handgretinger R, Rammensee HG, Steinle A. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction. *International journal of cancer. Journal international du cancer*. 2011
- Ardolino M, Zingoni A, Cerboni C, Cecere F, Soriani A, Iannitto ML, Santoni A. DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. *Blood*. 2011; 117:4778. [PubMed: 21406724]
- Arnon TI, Achdout H, Lieberman N, Gazit R, Gonen-Gross T, Katz G, Bar-Ilan A, Bloushtain N, Lev M, Joseph A, Kedar E, Porgador A, Mandelboim O. The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. *Blood*. 2004; 103:664. [PubMed: 14504081]
- Barber DF, Faure M, Long EO. LFA-1 contributes an early signal for NK cell cytotoxicity. *Journal of immunology*. 2004; 173:3653.
- Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. *Nature*. 2005; 434:864. [PubMed: 15829956]
- Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. *Science*. 1999; 285:727. [PubMed: 10426993]
- Benoit L, Wang X, Pabst HF, Dutz J, Tan R. Defective NK cell activation in X-linked lymphoproliferative disease. *Journal of immunology*. 2000; 165:3549.
- Billadeau DD, Brumbaugh KM, Dick CJ, Schoon RA, Bustelo XR, Leibson PJ. The Vav-Rac1 pathway in cytotoxic lymphocytes regulates the generation of cell-mediated killing. *Journal of Experimental Medicine*. 1998; 188:549. [PubMed: 9687532]
- Binstadt BA, Brumbaugh KM, Dick CJ, Scharenberg AM, Williams BL, Colonna M, Lanier LL, Kinet JP, Abraham RT, Leibson PJ. Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation. *Immunity*. 1996; 5:629. [PubMed: 8986721]
- Bix M, Liao NS, Zijlstra M, Loring J, Jaenisch R, Raulet D. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. *Nature*. 1991; 349:329. [PubMed: 1987491]
- Bloch-Queyrat C, Fondaneche MC, Chen R, Yin L, Relouzat F, Veillette A, Fischer A, Latour S. Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn. *The Journal of experimental medicine*. 2005; 202:181. [PubMed: 15998796]
- Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, Rousselot P, Tamouza R, Le Bouteiller P, Mahon FX, Steinle A, Charron D, Dombret H, Toubert A. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. *J Immunol*. 2006; 176:5108. [PubMed: 16585609]
- Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N, Vitale M, Moretta L, Lopez M, Moretta A. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. *J Exp Med*. 2003; 198:557. [PubMed: 12913096]
- Braig M, Schmitt CA. Oncogene-induced senescence: putting the brakes on tumor development. *Cancer Res*. 2006; 66:2881. [PubMed: 16540631]
- Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, Moretta A, West R, Xu W, Vivier E, Levin SD. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. *J Exp Med*. 2009; 206:1495. [PubMed: 19528259]
- Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. *Nature*. 1998; 391:795. [PubMed: 9486650]
- Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher

- B, Berdel J, Niessner H, Meier F, van den Broek M, Haring HU, Handgretinger R, Quintanilla-Martinez L, Fend F, Pesic M, Bauer J, Zender L, Schaller M, Schulze-Osthoff K, Rocken M. T-helper-1-cell cytokines drive cancer into senescence. *Nature*. 2013; 494:361. [PubMed: 23376950]
- Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. *The Journal of experimental medicine*. 2005; 202:1001. [PubMed: 16203869]
- Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. *Blood*. 2006; 107:159. [PubMed: 16150947]
- Burns GF, Triglia T, Werkmeister JA, Begley CG, Boyd AW. TLI SA1, a human T lineage-specific activation antigen involved in the differentiation of cytotoxic T lymphocytes and anomalous killer cells from their precursors. *The Journal of experimental medicine*. 1985; 161:1063. [PubMed: 2580933]
- Burshtyn D, Scharenberg A, Wagtmann N, Rajagopalan S, Peruzzi M, Kinet J-P, Long EO. Recruitment of tyrosine phosphatase HCP by the NK cell inhibitory receptor. *Immunity*. 1996; 4:77. [PubMed: 8574854]
- Campbell KS, Dessing M, Lopez-Botet M, Cella M, Colonna M. Tyrosine phosphorylation of a human killer inhibitory receptor recruits protein tyrosine phosphatase 1C. *Journal of Experimental Medicine*. 1996; 184:93. [PubMed: 8691154]
- Campisi J. Aging, Cellular Senescence, and Cancer. *Annual review of physiology*. 2012
- Cantoni C, Bottino C, Augugliaro R, Morelli L, Marcenaro E, Castriconi R, Vitale M, Pende D, Sivori S, Millo R, Biassoni R, Moretta L, Moretta A. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. *European Journal of Immunology*. 1999; 29:3148. [PubMed: 10540326]
- Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, Moretta L, Bottino C, Moretta A. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. *Cancer research*. 2004; 64:9180. [PubMed: 15604290]
- Cella M, Fujikawa K, Tassi I, Kim S, Latinis K, Nishi S, Yokoyama W, Colonna M, Swat W. Differential requirements for Vav proteins in DAP10- and ITAM-mediated NK cell cytotoxicity. *J Exp Med*. 2004; 200:817. [PubMed: 15365099]
- Cerboni C, Ardolino M, Santoni A, Zingoni A. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells. *Blood*. 2009; 113:2955. [PubMed: 19124832]
- Cerwenka A, Bakker ABH, McClanahan T, Wagner J, Wu J, Phillips JH, Lanier LL. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. *Immunity*. 2000; 12:721. [PubMed: 10894171]
- Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. *Proc Natl Acad Sci U S A*. 2001; 98:11521. [PubMed: 11562472]
- Champsaur M, Beilke JN, Ogasawara K, Koszinowski UH, Jonjic S, Lanier LL. Intact NKG2D-Independent Function of NK Cells Chronically Stimulated with the NKG2D Ligand Rae-1. *J Immunol*. 2010
- Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. *Immunol Rev*. 2010; 235:267. [PubMed: 20536569]
- Chang YT, Wu CC, Shyr YM, Chen TC, Hwang TL, Yeh TS, Chang KP, Liu HP, Liu YL, Tsai MH, Chang YS, Yu JS. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. *PLoS One*. 2011; 6:e20029. [PubMed: 21625447]
- Chauveau A, Aucher A, Eissmann P, Vivier E, Davis DM. Membrane nanotubes facilitate long-distance interactions between natural killer cells and target cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107:5545. [PubMed: 20212116]
- Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. *Nature genetics*. 1996; 13:210. [PubMed: 8640228]

- Chitadze G, Bhat J, Lettau M, Janssen O, Kabelitz D. Generation of Soluble NKG2D Ligands: Proteolytic Cleavage, Exosome Secretion and Functional Implications. *Scandinavian journal of immunology*. 2013; 78:120. [PubMed: 23679194]
- Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. *Nature reviews. Molecular cell biology*. 2008; 9:616. [PubMed: 18594563]
- Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. *Cancer*. 1997; 79:2320. [PubMed: 9191519]
- Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. *Nature reviews. Cancer*. 2010; 10:51. [PubMed: 20029423]
- Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Revirion D, Gastaut JA, Pende D, Olive D, Moretta A. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. *Blood*. 2002; 99:3661. [PubMed: 11986221]
- Coudert JD, Scarpellino L, Gros F, Vivier E, Held W. Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. *Blood*. 2008; 111:3571. [PubMed: 18198346]
- Coudert JD, Zimmer J, Tomasello E, Cebecauer M, Colonna M, Vivier E, Held W. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. *Blood*. 2005; 106:1711. [PubMed: 15886320]
- Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. *J Exp Med*. 2002; 196:119. [PubMed: 12093876]
- Croxford JL, Tang ML, Pan MF, Huang CW, Kamran N, Phua CM, Chng WJ, Ng SB, Raulet DH, Gasser S. ATM-dependent spontaneous regression of early Emu-myc-induced murine B-cell leukemia depends on natural killer and T cells. *Blood*. 2013; 121:2512. [PubMed: 23349395]
- Davis JE, Smyth MJ, Trapani JA. Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity. *European journal of immunology*. 2001; 31:39. [PubMed: 11169436]
- Deguine J, Breart B, Lemaitre F, Di Santo JP, Bousso P. Intravital Imaging Reveals Distinct Dynamics for Natural Killer and CD8(+) T Cells during Tumor Regression. *Immunity*. 2010; 33:632. [PubMed: 20951068]
- Dennehy KM, Klimosch SN, Steinle A. Cutting edge: Nkp80 uses an atypical hemi-ITAM to trigger NK cytotoxicity. *Journal of immunology*. 2011; 186:657.
- Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. *The Journal of experimental medicine*. 2011; 208:1989. [PubMed: 21930769]
- Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. *Nature Immunology*. 2000; 1:119. [PubMed: 11248803]
- Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. *Nature*. 2001; 413:165. [PubMed: 11557981]
- Diefenbach A, Tomasello E, Lucas M, Jamieson AM, Hsia JK, Vivier E, Raulet DH. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. *Nat Immunol*. 2002; 3:1142. [PubMed: 12426565]
- Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, Hofsteenge J, Gratwohl A, Tichelli A, Paluszewska M, Wiktor-Jedrzejczak W, Kalberer CP, Wodnar-Filipowicz A. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. *Blood*. 2008; 111:1428. [PubMed: 17993609]
- Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. *Immunity*. 1994; 1:447. [PubMed: 7895156]

- Dong Z, Cruz-Munoz ME, Zhong MC, Chen R, Latour S, Veillette A. Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells. *Nat Immunol.* 2009; 10:973. [PubMed: 19648922]
- Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B, Vyas YM. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. *J Immunol.* 2003; 171:6891. [PubMed: 14662896]
- Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. *Nat Immunol.* 2002; 3:991. [PubMed: 12407406]
- Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. *Annu Rev Immunol.* 2004; 22:329. [PubMed: 15032581]
- Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, Weller M, Friese MA. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. *Brain.* 2006; 129:2416. [PubMed: 16891318]
- Elboim M, Gazit R, Gur C, Ghadially H, Betser-Cohen G, Mandelboim O. Tumor immunoediting by Nkp46. *J Immunol.* 2010; 184:5637. [PubMed: 20404273]
- Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D, Moscinski L, Wei S, Djeu JY, List AF. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. *Blood.* 2007; 109:4816. [PubMed: 17341666]
- Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, Costello RT. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. *Blood.* 2007; 109:323. [PubMed: 16940427]
- Fauriat C, Moretta A, Olive D, Costello RT. Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients. *Blood.* 2005; 106:2186. [PubMed: 15928036]
- Fernandez-Messina L, Ashiru O, Boutet P, Aguera-Gonzalez S, Skepper JN, Reyburn HT, Vales-Gomez M. Differential mechanisms of shedding of the glycosyl-phosphatidylinositol (GPI)-anchored NKG2D ligands. *J Biol Chem.* 2010
- Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, Buhning HJ, Dichgans J, Rammensee HG, Steinle A, Weller M. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. *Cancer Res.* 2003; 63:8996. [PubMed: 14695218]
- Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). *Journal of immunology.* 2004; 172:3994.
- Fuchs A, Colonna M. The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. *Seminars in cancer biology.* 2006; 16:359. [PubMed: 16904340]
- Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science.* 2006; 313:1960. [PubMed: 17008531]
- Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, Craft J, Yin Z. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. *J Exp Med.* 2003; 198:433. [PubMed: 12900519]
- Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. *Advances in cancer research.* 2001; 83:117. [PubMed: 11665717]
- Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F. HLA class I antigens in human tumors. *Advances in cancer research.* 1995; 67:155. [PubMed: 8571814]
- Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. *Immunology Today.* 1997; 18:89. [PubMed: 9057360]
- Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. *Nature.* 2005; 436:1186. [PubMed: 15995699]
- Gasser S, Raulet DH. Activation and self-tolerance of natural killer cells. *Immunol Rev.* 2006; 214:130. [PubMed: 17100881]

- Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, Andrews DM, Smyth MJ, Colonna M. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. *J Exp Med*. 2008; 205:2965. [PubMed: 19029380]
- Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M. NKG2D recruits two distinct adapters to trigger natural killer cell activation and costimulation. *Nature Immunology*. 2002; 3:1150. [PubMed: 12426564]
- Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC. Regulation of cutaneous malignancy by gammadelta T cells. *Science*. 2001; 294:605. [PubMed: 11567106]
- Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr. Kastriakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. *Nature*. 2005; 434:907. [PubMed: 15829965]
- Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. *Proceedings of the National Academy of Sciences of the United States of America*. 1996; 93:12445. [PubMed: 8901601]
- Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T- cell activation. *Nature*. 2002; 419:734. [PubMed: 12384702]
- Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NR, Raulet DH. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. *Immunity*. 2008; 28:571. [PubMed: 18394936]
- Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, Sayers TJ, Hudig D, Murphy WJ. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. *J Immunol*. 2008; 180:163. [PubMed: 18097016]
- Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell*. 2000; 100:57. [PubMed: 10647931]
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011; 144:646. [PubMed: 21376230]
- Hayakawa Y, Kelly JM, Westwood J, Darcy PK, Diefenbach A, Raulet DH, Smyth MJ. Tumor rejection mediated by NKG2D receptor-ligand interaction is strictly dependent on perforin. *J Immunol*. 2002; 169:5377. [PubMed: 12421908]
- Heinemann A, Zhao F, Pechlivanis S, Eberle J, Steinle A, Diederichs S, Schadendorf D, Paschen A. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. *Cancer research*. 2012; 72:460. [PubMed: 22102694]
- Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T, Steinle A, Salih HR. Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses. *Journal of immunology*. 2012; 189:1360.
- Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. *Cancer research*. 2005; 65:1089. [PubMed: 15705911]
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebba C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2010; 363:711. [PubMed: 20525992]
- Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. *J. Exp. Med*. 1991; 173:1017. [PubMed: 2007850]
- Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. *The Journal of experimental medicine*. 2013; 210:2057. [PubMed: 24043758]

- Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S, Yasui T, Kikutani H, Shibuya K, Shibuya A. Accelerated tumor growth in mice deficient in DNAM-1 receptor. *J Exp Med*. 2008; 205:2959. [PubMed: 19029379]
- Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. *Cancer*. 2000; 88:577. [PubMed: 10649250]
- Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. *J Hepatol*. 2005; 43:1013. [PubMed: 16168521]
- Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neubergh D, Anderson KC, Carrasco DR, Dranoff G. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. *Proc Natl Acad Sci U S A*. 2008
- Johnsen AC, Haux J, Steinkjer B, Nonstad U, Egeberg K, Sundan A, Ashkenazi A, Espevik T. Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. *Cytokine*. 1999; 11:664. [PubMed: 10479402]
- Jung H, Hsiung B, Pestal K, Procyk E, Raulet DH. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. *The Journal of experimental medicine*. 2012; 209:2409. [PubMed: 23166357]
- Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. *Nature*. 1994; 369:31. [PubMed: 8164737]
- Kaifu T, Escaliere B, Gastinel LN, Vivier E, Baratin M. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. *Cellular and molecular life sciences : CMLS*. 2011; 68:3531. [PubMed: 21877119]
- Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwalder M, Khan S, Gil J, Bruder D, Manns M, Schirmacher P, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S, Zender L. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. *Nature*. 2011; 479:547. [PubMed: 22080947]
- Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. *Nature*. 1986; 319:675. [PubMed: 3951539]
- Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, Yee H, Zender L, Lowe SW. Senescence of activated stellate cells limits liver fibrosis. *Cell*. 2008; 134:657. [PubMed: 18724938]
- Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, Pende D, Groh V, Biassoni R, Hoglund P, Kato M, Shibuya K, Schadendorf D, Anichini A, Ferrone S, Velardi A, Karre K, Shibuya A, Carbone E, Colucci F. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. *The Journal of clinical investigation*. 2009; 119:1251. [PubMed: 19349689]
- Lanier LL. NK cell receptors. *Annu Rev Immunol*. 1998; 16:359. [PubMed: 9597134]
- Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients. *J Immunol*. 2004a; 172:7335. [PubMed: 15187109]
- Lee KM, McNerney ME, Stepp SE, Mathew PA, Schatzle JD, Bennett M, Kumar V. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. *J Exp Med*. 2004b; 199:1245. [PubMed: 15123744]
- Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, Geraghty DE. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. *Proc Natl Acad Sci U S A*. 1998; 95:5199. [PubMed: 9560253]
- Lee RK, Spielman J, Zhao DY, Olsen KJ, Podack ER. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. *J Immunol*. 1996; 157:1919. [PubMed: 8757310]

- Li H, Lakshmikanth T, Garofalo C, Enge M, Spinnler C, Anichini A, Szekely L, Karre K, Carbone E, Selivanova G. Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. *Cell Cycle*. 2011; 10:3346. [PubMed: 21941086]
- Liu XV, Ho SS, Tan JJ, Kamran N, Gasser S. Ras Activation Induces Expression of Raet1 Family NK Receptor Ligands. *Journal of immunology*. 2012
- Liu Z, Eltoum IE, Guo B, Beck BH, Cloud GA, Lopez RD. Protective Immunosurveillance and Therapeutic Antitumor Activity of $\gamma\delta$ T Cells Demonstrated in a Mouse Model of Prostate Cancer. *J Immunol*. 2008; 180:6044. [PubMed: 18424725]
- Ljunggren H-G, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. *J. Exp. Med*. 1985; 162:1745. [PubMed: 3877776]
- Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. *Immunol. Today*. 1990; 11:237. [PubMed: 2201309]
- Long E. Regulation of immune responses through inhibitory receptors. *Annual Review of Immunology*. 1999; 17:875.
- Long EO, Sik Kim H, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. *Annual review of immunology*. 2013; 31:227.
- Lord CJ, Ashworth A. The DNA damage response and cancer therapy. *Nature*. 2012; 481:287. [PubMed: 22258607]
- Marten A, von Lilienfeld-Toal M, Buchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. *Int J Cancer*. 2006; 119:2359. [PubMed: 16929491]
- Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. *Nat Immunol*. 2004; 5:1260. [PubMed: 15531883]
- Masson D, Jarry A, Baury B, Blanchardie P, Laboisie C, Lustenberger P, Denis MG. Overexpression of the CD155 gene in human colorectal carcinoma. *Gut*. 2001; 49:236. [PubMed: 11454801]
- Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. *Nature*. 2012; 482:400. [PubMed: 22318521]
- McNerney ME, Guzier D, Kumar V. 2B4 (CD244) - CD48 interactions provide a novel MHC class I-independent system for NK cell self-tolerance in mice. *Blood*. 2005
- Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taieb J, Delahaye NF, Flament C, Emile JF, Le Cesne A, Zitvogel L. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. *Cancer research*. 2009; 69:3563. [PubMed: 19351841]
- Mentlik AN, Sanborn KB, Holzbaur EL, Orange JS. Rapid lytic granule convergence to the MTOC in natural killer cells is dependent on dynein but not cytolytic commitment. *Molecular biology of the cell*. 2010; 21:2241. [PubMed: 20444980]
- Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L. Receptors for HLA class-I molecules in human natural killer cells. *Ann. Rev. Immunol*. 1996; 14:619. [PubMed: 8717527]
- Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytotoxicity. *Annu Rev Immunol*. 2001; 19:197. [PubMed: 11244035]
- Moretta A, Marcenaro E, Sivori S, Della Chiesa M, Vitale M, Moretta L. Early liaisons between cells of the innate immune system in inflamed peripheral tissues. *Trends in immunology*. 2005; 26:668. [PubMed: 16198147]
- Nakajima H, Cella M, Bouchon A, Grierson HL, Lewis J, Duckett CS, Cohen JI, Colonna M. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. *European journal of immunology*. 2000; 30:3309. [PubMed: 11093147]
- Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, Muthuswamy L, Krasnitz A, McCombie WR, Hicks J, Wigler M. Tumour evolution inferred by single-cell sequencing. *Nature*. 2011; 472:90. [PubMed: 21399628]

- Nuckel H, Switala M, Sellmann L, Horn PA, Durig J, Duhrsen U, Kuppers R, Grosse-Wilde H, Rebmann V. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. *Leukemia*. 2010; 24:1152. [PubMed: 20428196]
- O'Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiew SF, Teng MW, Smyth MJ, Schreiber RD, Bui JD. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. *The Journal of experimental medicine*. 2012; 209:1869. [PubMed: 22927549]
- Ogasawara K, Benjamin J, Takaki R, Phillips JH, Lanier LL. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. *Nat Immunol*. 2005; 6:938. [PubMed: 16086018]
- Olcese L, Lang P, Vely F, Cambiaggi A, Marguet D, Blery M, Hippen KL, Biassoni R, Moretta A, Moretta L, Cambier J, Vivier E. Human and mouse killer-cell inhibitory receptors recruit Ptp1c and Ptp1d protein tyrosine phosphatases. *J. Immunol*. 1996; 156:4531. [PubMed: 8648092]
- Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, Girardi M, Hayday AC. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. *Nat Immunol*. 2005; 6:928. [PubMed: 16116470]
- Paschen A, Sucker A, Hill B, Moll I, Zaparka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, Steinle A, Schadendorf D, Ugurel S. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. *Clin Cancer Res*. 2009; 15:5208. [PubMed: 19671853]
- Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, Marcenaro E, Accame L, Malaspina A, Biassoni R, Bottino C, Moretta L, Moretta A. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. *Journal of Experimental Medicine*. 1999; 190:1505. [PubMed: 10562324]
- Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L, Biassoni R, Moretta A. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. *Journal of Experimental Medicine*. 1998; 188:953. [PubMed: 9730896]
- Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. *Cell death and differentiation*. 2003; 10:26. [PubMed: 12655293]
- Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Boll B, Simhadri VL, Borchmann P, McKinnon PJ, Hallek M, Engert A. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. *Immunity*. 2007; 27:965. [PubMed: 18055229]
- Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. *Nat Rev Immunol*. 2003; 3:781. [PubMed: 14523385]
- Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. *Annual review of immunology*. 2013; 31:413.
- Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. *Annu Rev Immunol*. 2001; 19:291. [PubMed: 11244039]
- Ravetch JV, Lanier LL. Immune inhibitory receptors. *Science*. 2000; 290:84. [PubMed: 11021804]
- Rosen DB, Araki M, Hamerman JA, Chen T, Yamamura T, Lanier LL. A Structural basis for the association of DAP12 with mouse, but not human, NKG2D. *J Immunol*. 2004; 173:2470. [PubMed: 15294961]
- Ruckrich T, Steinle A. Attenuated natural killer (NK) cell activation through C-type lectin-like receptor NKp80 is due to an anomalous hemi-immunoreceptor tyrosine-based activation motif (HemITAM) with impaired Syk kinase recruitment capacity. *The Journal of biological chemistry*. 2013; 288:17725. [PubMed: 23609447]
- Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. *Blood*. 2003; 102:1389. [PubMed: 12714493]
- Salih HR, Goehlsdorf D, Steinle A. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. *Hum Immunol*. 2006; 67:188. [PubMed: 16698441]

- Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. *Journal of immunology*. 2002; 169:4098.
- Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science*. 2011; 331:1565. [PubMed: 21436444]
- Scott JL, Dunn SM, Jin B, Hillam AJ, Walton S, Berndt MC, Murray AW, Krissansen GW, Burns GF. Characterization of a novel membrane glycoprotein involved in platelet activation. *The Journal of biological chemistry*. 1989; 264:13475. [PubMed: 2760031]
- Seaman W, Sleisenger M, Eriksson E, Koo G. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. *J. Immunol*. 1987; 138:4539. [PubMed: 3584981]
- Seliger B, Ritz U, Abele R, Bock M, Tampe R, Sutter G, Drexler I, Huber C, Ferrone S. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. *Cancer research*. 2001; 61:8647. [PubMed: 11751378]
- Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. *Nature*. 2001; 410:1107. [PubMed: 11323675]
- Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL, Phillips JH. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. *Immunity*. 1996; 4:573. [PubMed: 8673704]
- Shibuya K, Lanier LL, Phillips JH, Ochs HD, Shimizu K, Nakayama E, Nakauchi H, Shibuya A. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. *Immunity*. 1999; 11:615. [PubMed: 10591186]
- Shibuya K, Shirakawa J, Kameyama T, Honda S, Tahara-Hanaoka S, Miyamoto A, Onodera M, Sumida T, Nakauchi H, Miyoshi H, Shibuya A. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. *The Journal of experimental medicine*. 2003; 198:1829. [PubMed: 14676297]
- Shilling HG, Young N, Guethlein LA, Cheng NW, Gardiner CM, Tyan D, Parham P. Genetic control of human NK cell repertoire. *J Immunol*. 2002; 169:239. [PubMed: 12077250]
- Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. *Nature reviews. Molecular cell biology*. 2013; 14:197.
- Simhadri VR, Reiniers KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, Kufer TA, Engert A, Pogge von Strandmann E. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. *PLoS ONE*. 2008; 3:e3377. [PubMed: 18852879]
- Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R, Moretta L, Moretta A. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. *European Journal of Immunology*. 1999; 29:1656. [PubMed: 10359120]
- Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C, Moretta L, Moretta A. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. *J Exp Med*. 1997; 186:1129. [PubMed: 9314561]
- Sloan KE, Eustace BK, Stewart JK, Zehetmeier C, Torella C, Simeone M, Roy JE, Unger C, Louis DN, Ilag LL, Jay DG. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. *BMC cancer*. 2004; 4:73. [PubMed: 15471548]
- Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. *Int Immunol*. 2001; 13:459. [PubMed: 11282985]
- Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA, Scalzo AA. Perforin is a major contributor to NK cell control of tumor metastasis. *Journal of Immunology*. 1999; 162:6658.
- Song H, Kim J, Cosman D, Choi I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. *Cell Immunol*. 2006; 239:22. [PubMed: 16630603]
- Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, Cippitelli M, Fionda C, Petrucci MT, Guarini A, Foa R, Santoni A. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-

cell susceptibility and is associated with a senescent phenotype. *Blood*. 2009; 113:3503. [PubMed: 19098271]

Spaggiari GM, Carosio R, Pende D, Marcenaro S, Rivera P, Zocchi MR, Moretta L, Poggi A. NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors Nkp30 and Nkp46. *Eur J Immunol*. 2001; 31:1656. [PubMed: 11385609]

Stanietsky N, Rovis TL, Glasner A, Seidel E, Tsukerman P, Yamin R, Enk J, Jonjic S, Mandelboim O. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. *European journal of immunology*. 2013; 43:2138. [PubMed: 23677581]

Stewart SA, Weinberg RA. Telomeres: cancer to human aging. *Annu Rev Cell Dev Biol*. 2006; 22:531. [PubMed: 16824017]

Sun JC, Lanier LL. Cutting edge: viral infection breaks NK cell tolerance to "missing self". *J Immunol*. 2008; 181:7453. [PubMed: 19017932]

Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. *J Immunol*. 2002; 168:671. [PubMed: 11777960]

Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. *Proc Natl Acad Sci U S A*. 2008; 105:652. [PubMed: 18178624]

Tahara-Hanaoka S, Shibuya K, Onoda Y, Zhang H, Yamazaki S, Miyamoto A, Honda S, Lanier LL, Shibuya A. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). *International immunology*. 2004; 16:533. [PubMed: 15039383]

Tangye SG, Phillips JH, Lanier LL, Nichols KE. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. *J Immunol*. 2000; 165:2932. [PubMed: 10975798]

Tassi I, Presti R, Kim S, Yokoyama WM, Gilfillan S, Colonna M. Phospholipase C-gamma 2 is a critical signaling mediator for murine NK cell activating receptors. *Journal of immunology*. 2005; 175:749.

Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. *The Journal of clinical investigation*. 2013; 123:966. [PubMed: 23454759]

Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A. Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2. *Cancer research*. 2011; 71:5998. [PubMed: 21764762]

Tokuyama M, Lorin C, Delebecque F, Jung H, Raulet DH, Coscoy L. Expression of the RAE-1 Family of Stimulatory NK-Cell Ligands Requires Activation of the PI3K Pathway during Viral Infection and Transformation. *PLoS Pathog*. 2011; 7:e1002265. [PubMed: 21966273]

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *The New England journal of medicine*. 2012; 366:2443. [PubMed: 22658127]

Upshaw JL, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. The isoforms of phospholipase C-gamma are differentially used by distinct human NK activating receptors. *Journal of immunology*. 2005; 175:213.

Vaidya SV, Stepp SE, McNerney ME, Lee JK, Bennett M, Lee KM, Stewart CL, Kumar V, Mathew PA. Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. *J Immunol*. 2005; 174:800. [PubMed: 15634901]

van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H. Decreased tumor surveillance in perforin-deficient mice. *J Exp Med*. 1996; 184:1781. [PubMed: 8920866]

- van den Broek MF, Kagi D, Zinkernagel RM, Hengartner H. Perforin dependence of natural killer cell-mediated tumor control in vivo. *European journal of immunology*. 1995; 25:3514. [PubMed: 8566046]
- van der Bruggen P, Traversari C, Chomez P, Lurquin C, de Plaen E, van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science*. 1991; 254:1643. [PubMed: 1840703]
- Vance RE, Kraft JR, Altman JD, Jensen PE, Raulet DH. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical MHC class I molecule Qa-1^b. *J Exp Med*. 1998; 188:1841. [PubMed: 9815261]
- Veilleux A. Immune regulation by SLAM family receptors and SAP-related adaptors. *Nature reviews. Immunology*. 2006; 6:56. [PubMed: 16493427]
- Vermijlen D, Luo D, Froelich CJ, Medema JP, Kummer JA, Willems E, Braet F, Wisse E. Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. *Journal of leukocyte biology*. 2002; 72:668. [PubMed: 12377935]
- Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. *Annual review of immunology*. 2011; 29:235.
- Vetter CS, Groh V, Thor Straten P, Spies T, Bockemuhl EB, Becker JC. Expression of stress-induced MHC class I related chain molecules on human melanoma. *The Journal of investigative dermatology*. 2002; 118:600. [PubMed: 11918705]
- Viaud S, Terme M, Flament C, Taieb J, Andre F, Novault S, Escudier B, Robert C, Caillat-Zucman S, Tursz T, Zitvogel L, Chaput N. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. *PLoS ONE*. 2009; 4:e4942. [PubMed: 19319200]
- Vitale M, Bottino C, Sileri S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A. Nkp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. *J. Exp. Med*. 1998; 187:2065. [PubMed: 9625766]
- Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. *Science*. 2011; 331:44. [PubMed: 21212348]
- von Lilienfeld-Toal M, Frank S, Leyendecker C, Feyler S, Jarmin S, Morgan R, Glasmacher A, Marten A, Schmidt-Wolf IG, Brossart P, Cook G. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. *Cancer immunology, immunotherapy : CII*. 2010; 59:829.
- Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. *Cell*. 2009; 137:413. [PubMed: 19410540]
- Wang H, Yang D, Xu W, Wang Y, Ruan Z, Zhao T, Han J, Wu Y. Tumor-derived soluble MICs impair CD3(+)CD56(+) NKT-like cell cytotoxicity in cancer patients. *Immunology letters*. 2008; 120:65. [PubMed: 18672004]
- Watson NF, Spendlove I, Madjd Z, McGilvray R, Green AR, Ellis IO, Scholefield JH, Durrant LG. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. *International journal of cancer. Journal international du cancer*. 2006; 118:1445. [PubMed: 16184547]
- Watzl C, Long EO. Signal transduction during activation and inhibition of natural killer cells. *Current protocols in immunology / edited by John E. Coligan ... [et al.] Chapter 11, Unit 11 9B*. 2010
- Welte S, Kuttruff S, Waldhauer I, Steinle A. Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. *Nat Immunol*. 2006
- Wiemann K, Mittrucker HW, Feger U, Welte SA, Yokoyama WM, Spies T, Rammensee HG, Steinle A. Systemic NKG2D Down-Regulation Impairs NK and CD8 T Cell Responses In Vivo. *J Immunol*. 2005; 175:720. [PubMed: 16002667]
- Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH. An activating immunoreceptor complex formed by NKG2D and DAP10. *Science*. 1999; 285:730. [PubMed: 10426994]

- Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. *Nature*. 2007; 445:656. [PubMed: 17251933]
- Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. *J Exp Med*. 1998; 188:2375. [PubMed: 9858524]
- Zingoni A, Ardolino M, Santoni A, Cerboni C. NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses. *Frontiers in immunology*. 2012; 3:408. [PubMed: 23316196]
- Zompi S, Hamerman JA, Ogasawara K, Schweighoffer E, Tybulewicz VL, Santo JP, Lanier LL, Colucci F. NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. *Nat Immunol*. 2003; 4:565. [PubMed: 12740576]

Table 1

NK cell receptors with possible roles in tumor immune surveillance

Receptor	Adaptor protein(s)	Ligand(s)	Consequence of engagement
NKG2D (CD314)	DAP10 / DAP12	NKG2D ligands	Cytotoxicity / IFN- γ
NKp30(CD337)	CD3 ζ -CD3 ζ / CD3 ζ -Fc ϵ RI γ	B7-H6, BAG-6	Cytotoxicity / IFN- γ
NKp44 (CD336)	DAP12	viral HA, HN, MLL5	Cytotoxicity / IFN- γ
NKp46 (CD335)	Fc ϵ RI γ -CD3 ζ	viral HA, HN, ?	Cytotoxicity / IFN- γ
2B4 (CD244)	SAP/EAT2/ERT	CD48	Cytotoxicity / IFN- γ
NTBA (Ly108)	SAP/EAT2/ERT	NTBA	Cytotoxicity / IFN- γ
CD84	SAP/EAT2/ERT	CD84	Cytotoxicity? / IFN- γ ?
CRACC (CD319)	SAP/EAT2/ERT	CRACC	Cytotoxicity? / IFN- γ ?
DNAM-1 (CD226)	FYNT	PVR, Nectin-2	Adhesion
TACTILE (CD96)	FYNT	PVR, Nectin-2	Adhesion
NKp80 (KLRF1)	?	AICL	Cytotoxicity / IFN- γ

AICL: Activation-induced C-type lectin, HA: Haemagglutinin, HN: Haemagglutinin-neuraminidase, NKG2D ligands: MIC-A, MIC-B, ULBP1-6, MULT-1, RAE-1 α - ϵ , H60a-c, PVR: Poliovirus receptor.

Table 2

How NK cells become activated during cancer development.

NK cells may be come activated and undergo expansion to eliminate cancer cells in several ways:	
1	Recognizing tumor-induced immune-activating ligands on the host cells via activating receptors.
2	Responding to tumor cells that have lost expression of MHC or other immune-inhibitory ligands.
3	Reacting to activating cytokines (IFN- α/β , IL-12, IL-15, IL-18, IL-21) produced by tumor cells or by other immune cells stimulated by tumor cells.
4	By interaction with tumor infiltrating and tumor-associated immune cells e.g., DCs or macrophages.

Table 3

Possible mechanisms of tumor evasion of the NK cell response

1	Loss of expression of activating ligands for NK receptors such as NKG2D, NKp46 or DNAM-1.
2	Secreting/shedding soluble ligands for activating NK receptors e.g, NKG2D, thereby reducing ligand expression on the tumor surface, and in some cases inhibiting NK cell recognition and function.
3	Persistent stimulation of NK cells in the absence of inflammatory cytokines, which may induce a state of NK cell anergy.
4	Loss of tumor suppressors that induce secretion of chemokines that recruit NK cells.
5	Modulation of the tumor microenvironment resulting in secretion of immunosuppressive cytokines e.g, IL-10 and TGF- β .